Treatment Action Group welcomes the flurry of tuberculosis (TB) data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). This statement includes a summary of major findings, TAG’s take on them, and a more detailed overview of key findings.
Due to the late cancellation of the in-person Conference on Retroviruses and Opportunistic Infections (CROI), the 2020 Pre-CROI Community HIV Cure Research Workshop took place via Zoom conference on Saturday, March 7th. We thank all presenters, panelists and participants -…
This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…
A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.
A resource listing of articles, reports, websites, and ongoing clinical trials related to the research effort to cure HIV infection.
An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.